<DOC>
	<DOCNO>NCT00075192</DOCNO>
	<brief_summary>This multi-center , open label , randomize study . Patients randomize one follow arm allocation ratio 3:1 , respectively : Arm A : CP-675,206 + neoadjuvant hormone therapy ( NHT ) OR Arm B : neoadjuvant hormone therapy . After randomization , patient receive study treatment three cycle ( one cycle define 28 day ) . After completion three cycle , patient undergo prostatectomy pathology assessment complete central laboratory , Armed Forces Institute Pathology ( AFIP ) Washington , DC .</brief_summary>
	<brief_title>CP-675,206 With Neoadjuvant Hormone Therapy Patients With High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate , previously untreated Potential candidate radical prostatectomy basis patient 's general medical condition , performance status , life expectancy Potential candidate NHT prior prostatectomy , include high intermediate risk recurrence , base estimate risk biochemical recurrence : High risk category : PSA &gt; 20 Gleason score 8 cT2c/cT3 OR Intermediate risk category : PSA &gt; 10 d20 Gleason score 7 cT2b No evidence metastatic disease physical examination , bone scan , computed tomography , MRI , abdomen pelvis Age &gt; 18 year ECOG performance status 01 Adequate bone marrow , hepatic , renal function determine within 2 week prior start therapy Availability prostatectomy specimen histological analysis Armed Forces Institute Pathology Prior hormone therapy , radiation , chemotherapy , immunologic therapy prostate cancer History , significant risk , chronic inflammatory autoimmune disease Potential requirement systemic corticosteroid surgery base prior history History autoimmune colitis chronic GI condition associate diarrhea bleeding , current acute colitis origin Any serious uncontrolled medical disorder active infection would impair ability receive study treatment subsequent prostatectomy Coexisting malignancy except basal squamous cell carcinoma skin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>